In collaboration with neurologists and clinical research centres in North America and Europe, TauRx has started a new clinical trial, named LUCIDITY. The trial uses FDG-PET imaging and a composite cognitive functional/scale to confirm the benefits seen with its lead compound, LMTX®, in delaying the progression of Alzheimer’s disease. LUCIDITY is aimed at patients with Early Alzheimer’s disease and the treatment duration is 9 months. Study subjects completing the study will be eligible for continued use of LMTX® under an expanded access programme.
LUCIDITY is now recruiting in sites across North America and Europe. For further information, and to understand the eligibility criteria for the LUCIDITY trial, or to find a site closest to you, please use the following link: https://clinicaltrials.gov/ct2/show/NCT03446001?term=TRX0237&rank=5
TauRx’s tau aggregation inhibitors (TAIs) are the product of nearly 30 years of research, preclinical and clinical investigations.
The company’s second-generation TAI, LMTX®, has now completed three separate Phase 3 trials: two in Alzheimer's disease and one in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD). For more information on the Phase 3 trials, please click on the Phase 3 button below.